229 related articles for article (PubMed ID: 28252048)
1. Identification of serum protein biomarkers for utrophin based DMD therapy.
Guiraud S; Edwards B; Squire SE; Babbs A; Shah N; Berg A; Chen H; Davies KE
Sci Rep; 2017 Mar; 7():43697. PubMed ID: 28252048
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
4. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
Ito M; Ehara Y; Li J; Inada K; Ohno K
Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
[TBL] [Abstract][Full Text] [Related]
5. Microarray analysis of mdx mice expressing high levels of utrophin: therapeutic implications for dystrophin deficiency.
Baban D; Davies KE
Neuromuscul Disord; 2008 Mar; 18(3):239-47. PubMed ID: 18343112
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.
Coenen-Stass AM; McClorey G; Manzano R; Betts CA; Blain A; Saleh AF; Gait MJ; Lochmüller H; Wood MJ; Roberts TC
Sci Rep; 2015 Nov; 5():17014. PubMed ID: 26594036
[TBL] [Abstract][Full Text] [Related]
7. Utrophin upregulation in Duchenne muscular dystrophy.
Hirst RC; McCullagh KJ; Davies KE
Acta Myol; 2005 Dec; 24(3):209-16. PubMed ID: 16629055
[TBL] [Abstract][Full Text] [Related]
8. Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle.
Kennedy TL; Moir L; Hemming S; Edwards B; Squire S; Davies K; Guiraud S
Skelet Muscle; 2017 Oct; 7(1):22. PubMed ID: 29065908
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
[TBL] [Abstract][Full Text] [Related]
10. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
[TBL] [Abstract][Full Text] [Related]
11. Expression of full-length utrophin prevents muscular dystrophy in mdx mice.
Tinsley J; Deconinck N; Fisher R; Kahn D; Phelps S; Gillis JM; Davies K
Nat Med; 1998 Dec; 4(12):1441-4. PubMed ID: 9846586
[TBL] [Abstract][Full Text] [Related]
12. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.
Soblechero-Martín P; López-Martínez A; de la Puente-Ovejero L; Vallejo-Illarramendi A; Arechavala-Gomeza V
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):711-723. PubMed ID: 33999469
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 induces overexpression of the sarcolemmal utrophin in neonatal mdx skeletal muscle.
Fujimori K; Itoh Y; Yamamoto K; Miyagoe-Suzuki Y; Yuasa K; Yoshizaki K; Yamamoto H; Takeda S
Hum Gene Ther; 2002 Mar; 13(4):509-18. PubMed ID: 11874629
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice.
Nguyen HH; Jayasinha V; Xia B; Hoyte K; Martin PT
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5616-21. PubMed ID: 11960016
[TBL] [Abstract][Full Text] [Related]
15. Current Translational Research and Murine Models For Duchenne Muscular Dystrophy.
Rodrigues M; Echigoya Y; Fukada SI; Yokota T
J Neuromuscul Dis; 2016 Mar; 3(1):29-48. PubMed ID: 27854202
[TBL] [Abstract][Full Text] [Related]
16. [Study on the gene knockout model mice of Duchenne muscular dystrophy].
Chen S; Zhang C; Liu X; Gao L; Zhang W; Huang W; Lu X; Wang Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):210-3. PubMed ID: 12947691
[TBL] [Abstract][Full Text] [Related]
17. N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.
Crowe KE; Shao G; Flanigan KM; Martin PT
J Neuromuscul Dis; 2016 May; 3(2):247-260. PubMed ID: 27854211
[TBL] [Abstract][Full Text] [Related]
18. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
Hathout Y; Marathi RL; Rayavarapu S; Zhang A; Brown KJ; Seol H; Gordish-Dressman H; Cirak S; Bello L; Nagaraju K; Partridge T; Hoffman EP; Takeda S; Mah JK; Henricson E; McDonald C
Hum Mol Genet; 2014 Dec; 23(24):6458-69. PubMed ID: 25027324
[TBL] [Abstract][Full Text] [Related]
19. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
[TBL] [Abstract][Full Text] [Related]
20. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
